Invion Doses First Patient in Phase I/II Skin Cancer Trial
Filed with ASX · · 3 pages · English
Earlier from Invion
- Consolidation/Split - IVX
- Invion Limited (ASX: IVX) Prostate Cancer Trial Results
- Ph 2 Prostate Cancer Results Strong Safety and 40% Response
- Invion secures funding through an institutional placement
- Agreement with Major South Korean Pharma Group Hanlim
Later from Invion
- Activities Report and Appendix 4C
- Oesophageal Cancer Collaboration and Funding Agreement
- Completion Of Placement to Accelerate Clinical Programs
- Share Purchase Agreement Termination and Tranche Repayment
- Appendix 4C and Quarterly Activities Report - March 2025
Follow Invion into a list and get an email when it puts out news.
Follow Invion